Agios Pharmaceuticals (NASDAQ:AGIO) Price Target Raised to $34.00 at JPMorgan Chase & Co.
Steady2 outlets reported this in 2 reports over 2 days
Fri, 7 August 2026Thu, 20 August 2026
What it is about
Sarah GheuensNews Ratings For Agios Pharmaceuticals DailyCitigroupAnalyst Recommendations For Agios PharmaceuticalsDana-Farber Cancer InstituteAssetmark IncAgios Pharmaceuticals Company ProfileCaitong International Asset Management CoAgios PharmaceuticalsAgios Pharmaceuticals Price PerformanceBroad InstituteSecurities Exchange CommissionJpmorgan Chase CoInstitutional Trading Of Agios PharmaceuticalsRoyal BankNewedge AdvisorsDana-Farber Cancer Institute, Massachusetts, United StatesMassachusetts, United StatesCambridge, Cambridgeshire, United KingdomCanada
Who published it, and when
original reportfirst to report
themarketsdaily.com
dailypolitical.com
7 Aug, 15:54over 13 days20 Aug, 07:56
How it spread - 2 original reports
Fri, 7 August 2026
1 report- themarketsdaily.com15:54first to report
Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) had its price objective increased by equities research analysts at JPMorgan Chase & Co. from $31.00 to $34.00 in a report released on Friday,Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside […]
Thu, 20 August 2026
1 report- dailypolitical.com07:56
A number of firms have modified their ratings and price targets on shares of Agios Pharmaceuticals (NASDAQ: AGIO) recently: 8/7/2026 – Agios Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $31.00 to $34.00. They now have a “neutral” rating on the stock. 7/31/2026 – Agios Pharmaceuticals had its price target raised […]